Symbiosis secures FDA viral vector process approval

5 Oct 2018

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Symbiosis Pharmaceutical Services has reported FDA approval for its viral vector manufacturing fill/finish process at its biologics manufacturing facility located in Scotland, UK.

Symbiosis secures FDA viral vector process approval

Symbiosis recently hosted a successful inspection by the FDA for the aseptic manufacture of viral vector products for commercial supply into the US market at its GMP manufacturing facility, which has been licensed by the UK government's regulators, the MHRA, since 2012.

Colin MacKay, CEO at Symbiosis Pharmaceutical Services, commented: “The approval of this process at Symbiosis by the FDA is testament to our technical experience, capabilities, and specialist understanding of viral vector filling in compliance with the highest of regulatory standards.

“We have been honing our niche viral vector handling and manufacturing skills for several years and have dedicated resource and effort to maintaining the strict quality standards and expertise required to make the commercial GMP sterile filling of viral vectors a core capability at Symbiosis.

“This FDA inspection milestone is directly supportive of our recently reported success in being awarded a £1.9 million (US$ 2.4 million) grant from the UK government's funding body, Innovate UK, which was directed at strengthening the position of Symbiosis as a centre of excellence as part of the viral vector drug development supply chain, and firmly consolidating the commercial viral vector manufacturing capability of the UK as a global leader in this field.

“The FDA approval of Symbiosis, alongside its Innovate UK grant success, represents a significant positive indicator which supports the development of world-leading capabilities for clinical and commercial production of gene and immunotherapy viral vector drug substance and drug product manufacturing in the UK.”

MacKay continued: “Our ability to offer rapid access to sterile manufacturing slots has been a key competitive differentiator compared with the larger CDMOs in the outsourcing marketplace and has succeeded in leading to long-term relationships being built with pre-clinical, Phase I-III, and now commercial-stage biotech and pharma companies worldwide.”

Read More

Related news

SIRIO Pharma opens multimillion gummy production plant

SIRIO Pharma opens multimillion gummy production plant

18 Oct 2018

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

Read more 
Tjoapack and Veratrak launch EPOCH initiative

Tjoapack and Veratrak launch EPOCH initiative

17 Oct 2018

The virtual platform is designed to allow the healthcare industry to effectively research and explore new technologies that will help to shape the future of the pharmaceutical supply chain.

Read more 
Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

16 Oct 2018

The investment increases the overall capacity and capabilities of the facility, and its flexibility.

Read more 
Particle Sciences to open new commercial facility

Particle Sciences to open new commercial facility

15 Oct 2018

New facility will offer customers the full range of services from development through to commercial-scale manufacturing

Read more 
Generics companies to move away from little white pills

Generics companies to move away from "little white pills"

14 Oct 2018

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Read more 
Pharma manufacturers warned to invest in continuous manufacturing

Pharma manufacturers warned to invest in continuous manufacturing

11 Oct 2018

CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.

Read more 
New portable and ready-to-use upper respiratory drug delivery solution

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Read more 
CPhI Worldwide announces the winners  of the 15th Pharma Awards

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Micro-Sphere increases capsule filling capacity

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Read more